Page last updated: 2024-09-04

docetaxel anhydrous and Hematologic Neoplasms

docetaxel anhydrous has been researched along with Hematologic Neoplasms in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arslan, C; Uslu, R1
Becker, PS; Cassaday, RD; De Padova, N; Lindstrom, S; Puri, A; Ulrickson, ML1
Chow, LW; Yip, AY1

Other Studies

3 other study(ies) available for docetaxel anhydrous and Hematologic Neoplasms

ArticleYear
Secondary haematological malignancies in the BCIRG 001 study.
    The Lancet. Oncology, 2013, Volume: 14, Issue:3

    Topics: Cyclophosphamide; Docetaxel; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Taxoids

2013
Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm.
    American journal of hematology, 2017, Volume: 92, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids

2017
Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles.
    Breast cancer (Tokyo, Japan), 2006, Volume: 13, Issue:2

    Topics: Adult; Aged; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; China; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Immunohistochemistry; Incidence; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids

2006
chemdatabank.com